In Vivo Efficacy and Pharmacodynamic Analysis of RTX-321, an Engineered Allogeneic Artificial Antigen Presenting Red Cell Therapeutic

Mellissa J. Nixon*, Xuqing Zhang*, Shamael Dastagir, Albert Lee, Mengyao Luo, Annie Khamhoung, Andrea Schmidt, Douglas C. McLaughlin, Viral Amin, Chris Moore, Jennifer Mellen, Laurence Turka, Thomas J. Wickham, and Tiffany F. Chen

*Denotes equal contribution.

RTX-321 Audio Introduction